Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

PHASE2CompletedINTERVENTIONAL

Enrollment

1,500

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

November 4, 2019

Study Completion Date

November 14, 2022

Conditions

Malaria

Interventions

BIOLOGICAL

RTS,S/AS01E (Full dose)

Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).

BIOLOGICAL

RTS,S/AS01E (1/5th dose)

Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).

BIOLOGICAL

Rabies vaccine

Participants will receive intramuscular injection of rabies vaccine (0.1 ml).

Trial Locations (2)

GSK Investigational Site, Kisumu

GSK Investigational Site, Kumasi